MARKET

TBIO

TRANSLATE BIO, INC.
TBIO
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-46.8993
12.87
6.82
2,823,919,635.04
Seth Klarman's Translate Bio Stake Dissolved Upon Acquisition
GuruFocus News · 3d ago
Seth Klarman Dissolves Translate Bio Stake Upon Acquisition
GuruFocus News · 3d ago
Director Of Translate Bio Sold $78.09 Million In Stock
Jean-Francois Formela, Director at Translate Bio (NASDAQ:TBIO), made a large insider sell on September 14, according to a new SEC filing.
Benzinga · 5d ago
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator f...
Benzinga · 5d ago
Translate Bio Inc (TBIO) CEO Ronald C Jr Renaud Sold $36.3 million of Shares
GuruFocus News · 5d ago
Insider Sell: Translate Bio
MT Newswires · 5d ago
Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study
Zacks.com · 09/09 14:47
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatenin...
GlobeNewswire · 09/08 20:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TBIO. Analyze the recent business situations of TRANSLATE BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TBIO stock price target is 32.57 with a high estimate of 38.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 193
Institutional Holdings: 70.12M
% Owned: 92.76%
Shares Outstanding: 75.59M
TypeInstitutionsShares
Increased
41
8.80M
New
29
869.29K
Decreased
54
3.57M
Sold Out
29
5.65M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
President
Everett Sutherland
Chief Executive Officer/Director
Ronald Renaud
Chief Financial Officer
Brendan Smith
Chief Operating Officer/Secretary
Paul Burgess
Chief Accounting Officer
Robert Prentiss
Chief Scientific Officer
Richard Wooster
Other
Ann Barbier
Independent Director
Daniella Beckman
Independent Director
George Demetri
Independent Director
Jean-Francois Formela
Independent Director
Owen Hughes
Independent Director
Robert Meyer
Independent Director
Robert Plenge
No Data

Webull offers kinds of TRANSLATE BIO, INC. stock information, including NASDAQ:TBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBIO stock methods without spending real money on the virtual paper trading platform.